These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31319941)

  • 1. Evaluate Cutpoints: Adaptable continuous data distribution system for determining survival in Kaplan-Meier estimator.
    Ogłuszka M; Orzechowska M; Jędroszka D; Witas P; Bednarek AK
    Comput Methods Programs Biomed; 2019 Aug; 177():133-139. PubMed ID: 31319941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints.
    Jalava P; Kuopio T; Huovinen R; Laine J; Collan Y
    Anticancer Res; 2005; 25(3c):2535-42. PubMed ID: 16080489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis.
    Du X; Li XQ; Li L; Xu YY; Feng YM
    Breast Cancer Res Treat; 2013 Feb; 138(1):59-67. PubMed ID: 23397283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Risk Stratification for Breast Cancer Samples Based on the Expression Ratio of the Estrogen and Progesterone Receptor.
    Bendrat K; Fritz P; Müller S; Brockmöller S; Debus A; Friedrichs K; Lindner C; Brinkmann F; Heidemann E; Niendorf A
    Anticancer Res; 2016 Aug; 36(8):3855-63. PubMed ID: 27466487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization.
    Budczies J; Klauschen F; Sinn BV; Győrffy B; Schmitt WD; Darb-Esfahani S; Denkert C
    PLoS One; 2012; 7(12):e51862. PubMed ID: 23251644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
    Wu JR; Zhao Y; Zhou XP; Qin X
    Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
    Wirtz RM; Sihto H; Isola J; Heikkilä P; Kellokumpu-Lehtinen PL; Auvinen P; Turpeenniemi-Hujanen T; Jyrkkiö S; Lakis S; Schlombs K; Laible M; Weber S; Eidt S; Sahin U; Joensuu H
    Breast Cancer Res Treat; 2016 Jun; 157(3):437-46. PubMed ID: 27220750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival analysis in breast cancer using proteomic data from four independent datasets.
    Ősz Á; Lánczky A; Győrffy B
    Sci Rep; 2021 Aug; 11(1):16787. PubMed ID: 34408238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff.
    Duchnowska R; Sperinde J; Chenna A; Haddad M; Paquet A; Lie Y; Weidler JM; Huang W; Winslow J; Jankowski T; Czartoryska-Arłukowicz B; Wysocki PJ; Foszczyńska-Kłoda M; Radecka B; Litwiniuk MM; Zok J; Wiśniewski M; Zuziak D; Biernat W; Jassem J
    Clin Cancer Res; 2014 May; 20(10):2805-13. PubMed ID: 24668646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
    Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
    PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
    Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
    Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma.
    El-Gendi SM; Mostafa MF
    Pathol Oncol Res; 2016 Jul; 22(3):461-70. PubMed ID: 26597806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of LMTK3 is an independent factor indicating a poor prognosis in estrogen receptor α-positive breast cancer patients.
    Asano T; Sato S; Yoshimoto N; Endo Y; Hato Y; Dong Y; Takahashi S; Fujii Y; Toyama T
    Jpn J Clin Oncol; 2014 Oct; 44(10):889-97. PubMed ID: 25163465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
    Denkert C; Loibl S; Müller BM; Eidtmann H; Schmitt WD; Eiermann W; Gerber B; Tesch H; Hilfrich J; Huober J; Fehm T; Barinoff J; Jackisch C; Prinzler J; Rüdiger T; Erbstösser E; Blohmer JU; Budczies J; Mehta KM; von Minckwitz G
    Ann Oncol; 2013 Nov; 24(11):2786-93. PubMed ID: 23970015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®.
    Varga Z; Lebeau A; Bu H; Hartmann A; Penault-Llorca F; Guerini-Rocco E; Schraml P; Symmans F; Stoehr R; Teng X; Turzynski A; von Wasielewski R; Gürtler C; Laible M; Schlombs K; Joensuu H; Keller T; Sinn P; Sahin U; Bartlett J; Viale G
    Breast Cancer Res; 2017 May; 19(1):55. PubMed ID: 28490348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgelin-2 expression in breast cancer and its relationships with clinicopathological features and patient outcome.
    Hao R; Liu Y; Du Q; Liu L; Chen S; You H; Dong Y
    Breast Cancer; 2019 Nov; 26(6):776-783. PubMed ID: 31144206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
    BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast Cancer Subtype Classification Using 4-Plex Droplet Digital PCR.
    Chen W; Zheng J; Wu C; Liu S; Chen Y; Liu X; Du J; Wang J
    Clin Chem; 2019 Aug; 65(8):1051-1059. PubMed ID: 31010819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.